Stemline Therapeutics (STML) intends to offer and sell, subject to market conditions, 3,7 M shares in an offering.
STML intends to grant the underwriters a 30-day option to purchase up to an additional 555,000 shares of its common stock offered in the public offering.
J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering.